Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101214 | 0.78 | HCAR2 (0.56) | HCAR2HCAR3CYP1A2DRD2SIGMAR1 | |
| SCHEMBL5531839 | 0.76 | HCAR2 (0.57) | HCAR2HCAR3CYP1A2DRD2SIGMAR1 | |
| SCHEMBL11414250 | 0.76 | HCAR2 (0.53) | HCAR2HCAR3CYP1A2DRD2SIGMAR1 | |
| SCHEMBL3105605 | 0.75 | HCAR2 (0.68) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3100362 | 0.75 | HCAR2 (0.43) | HCAR2HCAR3CYP1A2DRD2SIGMAR1 | |
| SCHEMBL5522029 | 0.73 | HCAR2 (0.41) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL5520638 | 0.67 | HCAR2 (0.40) | HCAR2HCAR3CYP1A2DRD2SIGMAR1 | |
| SCHEMBL5521792 | 0.67 | HCAR2 (0.51) | HCAR2HCAR3CYP1A2DRD2SIGMAR1 | |
| SCHEMBL5526210 | 0.65 | HCAR2 (0.54) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL21881 | 0.63 | TDP1 (0.67) | TP53TDP1CYP1A2PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ABAT, G6PD, GLS2 | TP53 2531/4885TDP1 3356/4885HCAR2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.